Yi-Bin Chen, MD, discusses the work-up, diagnosis, and treatment of a 42-year-old woman with moderate steroid-refractory chronic graft-versus-host disease (GVHD).
Case: A 42-Year-Old Woman With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease
Initial Presentation
First-line Treatment
Second-line Treatment
Patient is now receiving ruxolitinib 10 mg orally twice daily, alongside 1 mg/kg/day steroids
Yi-Bin Chen, MD: Today we have a case of a 42-year-old woman who previously underwent a myeloablative unrelated donor allogeneic peripheral blood stem cell transplant for a diagnosis of acute myeloid leukemia. She received conventional tacrolimus and methotrexate for graft-versus-host disease prevention.
She did not experience any acute graft-versus-host disease, but about 11 months after transplant, the patient presented with moderately dry and painful eyes, mild muscle and joint pains, and a mild erythematous scaly rash on her face and her arms. At that point, a diagnosis of chronic graft-versus-host disease was made, and the patient was initially started on some steroid eyedrops for her dry eyes, some topical steroid cream for her rash, and oral prednisone at 0.5mg/kg daily as initial first-line therapy for chronic graft-versus-host disease.
After 4 weeks of treatment, the symptoms of her ocular chronic graft-versus-host disease had pretty much resolved, but the patient's skin rash, as well as muscle and joint pains, had worsened. The steroid dose was increased to 1mg/kg daily of oral prednisone. Despite this increase, the skin rash and the muscle and joint pains continued to worsen. At this point, a diagnosis of steroid-refractory chronic graft-versus-host disease was made, and the patient was started on ruxolitinib 10mg orally, twice daily, along with her 1mg/kg of oral prednisone.
This case is fairly representative of many cases that I see in my clinic, and I'm sure my colleagues too, for those of us who follow patients longitudinally after allergenic transplantation.
Transcript edited for clarity.
Survival Benefits Shown After Stem Cell Transplant With Orca-T Vs PTCy
February 26th 2024Orca-T demonstrated survival rates vs post-transplant cyclophosphamide in patients with hematologic malignancies receiving myeloablative conditioning, according to findings from a retrospective analysis.
Read More
Improving Access to Bone Marrow Transplant and Cellular Therapies
February 19th 2024Stem cell treatments offer hope for a variety of conditions. However, access to these potentially life-altering procedures is often hampered by social factors such as socioeconomic status, race, cultural background, and geographic location.
Read More
Acyclovir Prophylaxis Reduces Oral Mucositis Incidence in HSCT Recipients
February 18th 2024Adding prophylactic acyclovir therapy to the treatment regimen for patients undergoing a stem cell transplant reduced the rates of chemotherapy-induced oral mucositis, a common and significant adverse effect of the treatment.
Read More